10 results on '"Ye, Yingjiang"'
Search Results
2. hsa_circ_0000231 Promotes colorectal cancer cell growth through upregulation of CCND2 by IGF2BP3/miR-375 dual pathway
- Author
-
Zhang, Wei, Wang, Bo, Lin, Yilin, Yang, Yang, Zhang, Zhen, Wang, Quan, Zhang, Haoran, Jiang, Kewei, Ye, Yingjiang, Wang, Shan, and Shen, Zhanlong
- Published
- 2022
- Full Text
- View/download PDF
3. Robotic colorectal cancer surgery in China: a nationwide retrospective observational study
- Author
-
Xu, Jianmin, Tang, Bo, Li, Taiyuan, Jia, Baoqing, Yao, Hongliang, Zhao, Ren, Yuan, Weitang, Zhong, Ming, Chi, Pan, Zhou, Yanbing, Yang, Xiongfei, Cheng, Longwei, He, Yulong, Li, Yongxiang, Tong, Weidong, Sun, Xuejun, Jiang, Zhiwei, Wang, Kang, Li, Xiaorong, Wang, Xin, Wei, Ye, Chen, Zongyou, Zhang, Xiaoqiao, Ye, Yingjiang, Han, Fanghai, Tao, Kaixiong, Kong, Dalu, Wang, Ziqiang, Zhang, Cheng, He, Guodong, and Feng, Qingyang
- Published
- 2021
- Full Text
- View/download PDF
4. Application of Single-Cell Sequencing Technology in Research on Colorectal Cancer.
- Author
-
Zhao, Long, Wang, Quan, Yang, Changjiang, Ye, Yingjiang, and Shen, Zhanlong
- Subjects
COLORECTAL cancer ,PROGNOSIS ,CANCER research ,DRUG target ,METASTASIS - Abstract
Colorectal cancer (CRC) is the third most prevalent and second most lethal cancer globally, with gene mutations and tumor metastasis contributing to its poor prognosis. Single-cell sequencing technology enables high-throughput analysis of the genome, transcriptome, and epigenetic landscapes at the single-cell level. It offers significant insights into analyzing the tumor immune microenvironment, detecting tumor heterogeneity, exploring metastasis mechanisms, and monitoring circulating tumor cells (CTCs). This article provides a brief overview of the technical procedure and data processing involved in single-cell sequencing. It also reviews the current applications of single-cell sequencing in CRC research, aiming to enhance the understanding of intratumoral heterogeneity, CRC development, CTCs, and novel drug targets. By exploring the diverse molecular and clinicopathological characteristics of tumor heterogeneity using single-cell sequencing, valuable insights can be gained into early diagnosis, therapy, and prognosis of CRC. Thus, this review serves as a valuable resource for identifying prognostic markers, discovering new therapeutic targets, and advancing personalized therapy in CRC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Lymph node metastasis in T1-2 colorectal cancer: a population-based study.
- Author
-
Xiong, Xiaoyu, Wang, Chao, Cao, Jian, Gao, Zhidong, and Ye, Yingjiang
- Subjects
LYMPHATIC metastasis ,COLORECTAL cancer ,CARCINOEMBRYONIC antigen ,LYMPH node surgery ,MUCINOUS adenocarcinoma ,PROGRESSION-free survival - Abstract
Background: We performed this study to identify predictive factors for lymph node metastasis (LNM) and analyze the impact of LNM on the prognosis of patients with T1-2 colorectal cancer (CRC), with the intention of providing guidance for the treatment. Methods: The Surveillance Epidemiology and End Result database was used to identify 20,492 patients diagnosed with T1-2 stage CRC between 2010 and 2019, who underwent surgery and lymph node evaluation and had complete prognostic information. Clinicopathological data of patients with T1-2 stage colorectal cancer treated with surgery at Peking University People's Hospital from 2017 to 2021 with complete clinical information were retrieved. We identify and confirm the risk factors for positive lymph node involvement, and the results of follow-up were analyzed. Results: Age, preoperative carcinoembryonic antigen (CEA) level, perineural invasion, and primary tumor site were independent risk factors for LNM in T1-2 CRC based on the analysis of the SEER database, while tumor size and histology of mucinous carcinoma were also independent risk factors in T1 CRC. We then make the nomogram model for predicting LNM risk and showed an acceptable consistency and calibration capability. Survival analysis showed that LNM was an independent prognostic indicator of 5-year disease-specific survival (P = 0.013) and disease-free survival (P < 0.001) in patients with T1 and T2 CRC. Conclusion: Age, CEA level and primary tumor site should be taken into consideration before making the surgical decision in T1-2 CRC patients. The tumor size and histology of mucinous carcinoma also need to be thought about in T1 CRC. Conventional imaging tests do not appear to provide a precise assessment for this issue. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Prognostic Biomarker SPOCD1 and Its Correlation with Immune Infiltrates in Colorectal Cancer.
- Author
-
Gan, Lin, Yang, Changjiang, Zhao, Long, Wang, Shan, Gao, Zhidong, and Ye, Yingjiang
- Subjects
COLORECTAL cancer ,CANCER invasiveness ,BIOMARKERS ,MACROPHAGES ,GENE expression ,EXTRACELLULAR matrix - Abstract
The biological role of the spen paralogue and orthologue C-terminal domain containing 1 (SPOCD1) has been investigated in human malignancies, but its function in colorectal cancer (CRC) is unclear. This study investigated the association between SPOCD1 expression and clinicopathological features of CRC cases, as well as its prognostic value and biological function based on large-scale databases and clinical samples. The results showed that the expression level of SPOCD1 was elevated in CRC, which was generally associated with shortened survival time and poor clinical indexes, including advanced T, N, and pathologic stages. Multivariate Cox regression analysis showed that elevated SPOCD1 expression was an independent factor for poor prognosis in CRC patients. Functional enrichment analysis of SPOCD1 and its co-expressed genes revealed that SPOCD1 could act as an oncogene by regulating gene expression in essential functions and pathways of tumorigenesis, such as extracellular matrix organization, chemokine signaling pathways, and calcium signaling pathways. In addition, immune cell infiltration results showed that SPOCD1 expression was associated with various immune cells, especially macrophages. Furthermore, our findings suggested a possible function for SPOCD1 in the polarization of macrophages from M1 to M2 in CRC. In conclusion, SPOCD1 is a promising diagnostic and prognostic marker for CRC, opening new avenues for research and treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. N6‐methyladenosine demethylase ALKBH5 suppresses colorectal cancer progression potentially by decreasing PHF20 mRNA methylation.
- Author
-
Zhang, Zhen, Wang, Ling, Zhao, Long, Wang, Quan, Yang, Changjiang, Zhang, Mengmeng, Wang, Bo, Jiang, Kewei, Ye, Yingjiang, Wang, Shan, and Shen, Zhanlong
- Subjects
COLORECTAL cancer ,ADENOSINES ,CANCER invasiveness ,DEMETHYLASE ,MESSENGER RNA - Abstract
Background: As the most widespread mRNAs modification, N6‐methyladenosine (m6A) is dynamically and reversibly modulated by methyltransferases and demethylases. ALKBH5 is a major demethylase, and plays vital roles in the progression of cancers. However, the role and mechanisms of ALKBH5 in colorectal cancer (CRC) is unclear. Results: Herein, we discovered that in CRC, downregulated ALKBH5 was closely related to poor prognosis of CRC patients. Functionally, our results demonstrated that knockdown of ALKBH5 enhanced the proliferation, migration and invasion of LOVO and RKO in vitro, while overexpression of ALKBH5 inhibited the functions of these cells. The results also demonstrated that knockdown of ALKBH5 promoted subcutaneous tumorigenesis of LOVO in vivo, while overexpression of ALKBH5 suppressed this ability. Mechanistically, results from joint analyses of MeRIP‐seq and RNA‐seq indicated that PHF20 mRNA was a key molecule that was regulated by ALKBH5‐mediated m6A modification. Further experiments indicated that ALKBH5 may inhibit stability of PHF20 mRNA by removing the m6A modification of PHF20 mRNA 3′UTR. Conclusions: ALKBH5 suppresses CRC progression by decreasing PHF20 mRNA methylation. ALKBH5‐mediated m6A modification of PHF20 mRNA can serve as a hopeful strategy for the intervention and treatment of CRC. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. Risk factors of early postoperative bowel obstruction for patients undergoing selective colorectal surgeries.
- Author
-
Yang, Shuguang, Zhao, Huiying, Yang, Jianhui, An, Youzhong, Zhang, Hua, Bao, Yudi, Gao, Zhidong, and Ye, Yingjiang
- Subjects
PREOPERATIVE risk factors ,BOWEL obstructions ,PROCTOLOGY ,ELECTIVE surgery ,RECEIVER operating characteristic curves ,LOGISTIC regression analysis ,RETROSPECTIVE studies ,COLORECTAL cancer - Abstract
Objective: Postoperative bowel obstruction was one of the most severe complications in patients who received colorectal surgeries. This study aimed to explore risk factors of early postoperative obstruction and to construct a nomogram to predict the possibility of occurrence.Methods: The records of 1437 patients who underwent elective colorectal surgery in Peking University People's Hospital from 2015 to 2020 were retrospectively collected. Risk factors of early postoperative bowel obstruction were identified by logistic regression analysis and a nomogram was then constructed. Bootstrap was applied to verify the stability of the model.Results: COPD, hypothyroidism, probiotic indications, duration of antibiotics, and time to postoperative feeding were identified as independent risk factors and were put into a nomogram for predicting early postoperative bowel obstruction. The nomogram showed robust discrimination, with the area under the receiver operating characteristic curve was 0.894 and was well-calibrated.Conclusion: A nomogram including independent risk factors of COPD, hypothyroidism, probiotic indications, duration of antibiotics, and time to postoperative feeding were established to predict the risk of early postoperative bowel obstruction. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
9. Improving the efficiency of immune checkpoint inhibitors for metastatic pMMR/MSS colorectal cancer: Options and strategies.
- Author
-
Yang, Changjiang, Zhao, Long, Lin, Yilin, Wang, Shan, Ye, Yingjiang, and Shen, Zhanlong
- Subjects
- *
IMMUNE checkpoint inhibitors , *COLORECTAL cancer , *REGORAFENIB - Abstract
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment and been extensively used for patients with metastastic colorectal cancer (mCRC), especially those harboring deficient mismatch repair/ microsatellite instability (dMMR/MSI). However, the majority of mCRC are classified as proficient mismatch repair/microsatellite stability(pMMR/MSS) type characterized by a cold immune microenvironment, rendering them generally unresponsive to ICIs. How to improve the efficacy of ICIs for these patients is an important issue to be solved. On the one hand, it is urgent to discover the predictive biomarkers and clinical characteristics associated with effectiveness and expand the subset of pMMR/MSS mCRC patients who benefit from ICIs. Additionally, combined strategies are being explored to modulate the immune microenvironment of pMMR/MSS CRC and facilitate the conversion of cold tumors into hot tumors. In this review, we have focused on the recent advancements in the predictive biomarkers and combination therapeutic strategies with ICIs for pMMR/MSS mCRC. [Display omitted] • ICIs have enduring advantages for dMMR/MSI mCRC. However, the resistance to ICIs among the pMMR/MSS subgroup is prevalent. • The identification of predictive biomarkers and exploration of combined strategies carry significant implications. • The identification of novel biomarkers for predicting efficacy holds promise for expanding the beneficiaries. • The combined strategies aimed at transforming "cold" tumors into "hot" tumors will generate new prospects for pMMR/MMS CRC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Innate tumor killers in colorectal cancer.
- Author
-
Zhong, Fengyun, Lin, Yilin, Jing, Xiangxiang, Ye, Yingjiang, Wang, Shan, and Shen, Zhanlong
- Subjects
- *
COLORECTAL cancer , *INNATE lymphoid cells , *COLON tumors , *KILLER cells , *CYTOTOXIC T cells , *IMMUNITY - Abstract
Standard treatment of colorectal cancer (CRC) improves the prognosis of CRC patients, but it is still intractable to control the progression of metastatic CRC. Immune microenvironment and immunotherapies of CRC have received extensive attention in recent years, but present immunotherapies of CRC have mainly focused on T cells and therapeutic response is only observed in a small proportion of patients. Innate immune cells are the first-line of defense in the development of malignancies. Natural killer (NK) cells, NKT cells and γδT cells are three types of innate cells of lymphoid origin and show cytotoxicity against various tumor cells including CRC. Besides, in the development of CRC, they can also be inhibited or express regulatory type, promoting tumor progression. Researches about anti-tumorigenic and pro-tumorigenic mechanisms of these cells are ongoing and regulation of these cells is also being unearthed. Meanwhile, immunotherapies using these cells more or less have shown efficacy in animal models and some of them are under exploration in clinical trials. This review provides an overview of intrinsic properties of NK cell, NKT cell and γδT cell, and summarizes current related promising treatment strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.